Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:17 AM
Ignite Modification Date:
2025-12-25 @ 3:17 AM
NCT ID:
NCT01004705
Eligibility Criteria:
Inclusion Criteria:
* Male or female subjects ≥18 years of age
* Previously untreated LDL cholesterol ≥100 mg/dL and ≤180 mg/dL.
* Provide written informed consent.
Exclusion Criteria:
* Subjects with a medical condition requiring chronic pharmacological treatment
* On direct questioning and physical examination have evidence of any clinically significant chronic disease, including known or suspected human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.
* On direct questioning and physical examination have a medical history or evidence of abuse of drugs.
* Medical history of gastrointestinal bleeding or gastric or duodenal ulcer.
* Systolic pressure ≥140 mmHg or diastolic pressure \>89 mmHg requiring hypotensive medication.
* Presence of secondary dyslipidemia.
* Previous use of cholesterol lowering medication.
* Previous coronary artery bypass graft (CABG).
* Previous percutaneous transluminal coronary angioplasty (PTCA) with a drug-eluting stent.
* Presence of severe congestive heart failure (New York Heart Classification \[NYHC\] III IV).
* Presence of untreated or uncontrolled thyroid disease.
* Past or current medical history of asthma or aspirin induced asthma
* Previous hypersensitivity to ACE inhibitors (eg angioedema or cough).
* Previous hypersensitivity to ARBs.
* History of unstable angina.
* Serum creatinine \>2 mg/dL.
* Creatine phosphokinase (CPK) ≥5 x the upper limit of normal (ULN).
* Hemoglobin ≤12 g/dL (120 g/L) for male subjects or ≤10 g/dL (100 g/L) for female subjects.
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2 x ULN.
* Total bilirubin ≥1.5 x ULN.
* Serum triglyceride concentration ≥400 mg/dL.
* Subjects not using effective contraception methods (intra uterine device \[IUD\] and condom or diaphragm with spermicide and condom) during the study and for at least one month thereafter.
* Pregnant, lactating, breastfeeding, or intends to become pregnant during the course of the study (females only). All women must have a negative urine pregnancy test at the Screening Visit, be surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or have a postmenopausal status (no menses) for at least one year.
* Contraindications to or known or suspected hypersensitivity to aspirin, simvastatin or ramipril or their excipients.
* Presence of mental illness limiting the capacity for self-care.
* Presence of major systemic illnesses: renal disease, liver disease, neurological or psychiatric disease.
* Participation, in the 30 days preceding enrolment into the study, in any other clinical study in which investigational or marketed drugs were employed.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01004705
Study Brief:
Protocol Section:
NCT01004705